Why do cannabinoid receptors have more than one endogenous ligand?

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 367, Issue 1607, 2012, Pages 3216-3228

  Di Marzo, Vincenzo ^a   De Petrocellis, Luciano ^b  

^a CNR   (Italy)

^b CNR   (Italy)

Author keywords

Cannabinoid; Cannabinoid receptor type 1; Cannabinoid receptor type 2; Endocannabinoid; Endovanilloid; Transient receptor potential vanilloid type 1

Indexed keywords

EID: 84868107448     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2011.0382     Document Type: Review

References (147)

1. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564. (doi:10.1038/346561a0)
2. Munro, S., Thomas, K. L. & Abu-Shaar, M. 1993 Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65. (doi:10.1038/365061a0)
3. Devane, W. A. et al. 1992 Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949. (doi:10.1126/science.1470919)
4. Mechoulam, R. et al. 1995 Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90. (doi:10.1016/0006-2952(95)00109-D)
5. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A. & Waku, K. 1995 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97. (doi:10.1006/bbrc.1995.2437)
6. Di Marzo, V. & Fontana, A. 1995 Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostaglandins Leukot. Essent. Fatty Acids 53, 1-11. (doi:10.1016/0952-3278(95)90077-2 0952-3278(95)90077-2)
7. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V. & Mechoulam, R. 2009 Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 30, 515-527. (doi:10.1016/j.tips.2009.07.006)
8. Huang, S. M. et al. 2002 An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl Acad. Sci. USA 99, 8400-8405. (doi:10.1073/pnas.122196999)
9. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I. & Mechoulam, R. 2001 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl Acad. Sci. USA 98, 3662-3665. (doi:10.1073/pnas.061029898)
10. Porter, A. C. et al. 2002 Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301, 1020-1024. (doi:10.1124/jpet.301.3.1020)
11. Pertwee, R. G. et al. 2010 International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62, 588-631. (doi:10.1124/pr.110.003004)
12. Mackie, K., Devane, W. A. & Hille, B. 1993 Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44, 498-503.
13. Sugiura, T. et al. 1999 Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure- activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 274, 2794-2801. (doi:10.1074/jbc.274.5.2794)
14. McAllister, S. D., Griffin, G., Satin, L. S. & Abood, M. E. 1999 Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J. Pharmacol. Exp. Ther. 291, 618-626.
15. Rouzer, C. A., Ghebreselasie, K. & Marnett, L. J. 2002 Chemical stability of 2-arachidonylglycerol under biological conditions. Chem. Phys. Lipids 119, 69-82. (doi:10.1016/S0009-3084(02)00068-3)
16. Savinainen, J. R., Järvinen, T., Laine, K. & Laitinen, J. T. 2001 Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes. Br. J. Pharmacol. 134, 664-672. (doi:10.1038/sj.bjp.0704297)
17. Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H. & Waku, K. 2000 Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275, 605-612. (doi:10.1074/jbc.275.1.605)
18. Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D. & Hipkin, R. W. 2000 Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol. 57, 1045-1050.
19. Di Marzo, V. 2011 Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nat. Neurosci. 14, 9-15. (doi:10.1038/nn.2720)
20. Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T. & Ueda, N. 2004 Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279, 5298-5305. (doi:10.1074/jbc.M306642200)
21. Simon, G. M. & Cravatt, B. F. 2008 Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J. Biol. Chem. 283, 9341-9349. (doi:10.1074/jbc.M707807200)
22. Sun, Y. X., Tsuboi, K., Okamoto, Y., Tonai, T., Murakami, M., Kudo, I. & Ueda, N. 2004 Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem. J. 380, 749-756. (doi:10.1042/BJ20040031)
23. Liu, J. et al. 2008 Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54, 1-7. (doi:10.1016/j.neuropharm.2007.05.020)
24. Simon, G. M. & Cravatt, B. F. 2010 Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. Mol. Biosyst. 6, 1411-1418. (doi:10.1039/C000237B)
25. Bisogno, T. et al. 2003 Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163, 463-468. (doi:10.1083/jcb.200305129)
26. Gao, Y. et al. 2010 Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J. Neurosci. 30, 2017-2024. (doi:10.1523/JNEUROSCI.5693-09.2010)
27. Tanimura, A. et al. 2010 The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 65, 320-327. (doi:10.1016/j.neuron.2010.01.021)
28. Yoshino, H. et al. 2011 Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. J. Physiol. 589, 4857-4884. (doi:10.1113/jphysiol.2011.212225)
29. Sugiura, T., Kondo, S., Sukagawa, A., Tonegawa, T., Nakane, S., Yamashita, A., Ishima, Y. & Waku, K. 1996 Transacylase-mediated and phosphodiesterasemediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 240, 53-62. (doi:10.1111/j.1432-1033.1996.0053h.x)
30. Feledziak, M., Lambert, D.M., Marchand-Brynaert, J. & Muccioli, G. G. 2012 Inhibitors of the endocannabinoiddegrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis. Recent Pat. CNS Drug Discov. 7, 49-70. (doi:10.2174/157488912798842223)
31. Savinainen, J. R., Saario, S. M. & Laitinen, J. T. 2012 The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signaling through cannabinoid receptors. Acta Physiol. 204, 267-276. (doi:10.1111/j.1748-1716.2011.02280.x)
32. Lichtman, A. H., Blankman, J. L. & Cravatt, B. F. 2010 Endocannabinoid overload. Mol. Pharmacol. 78, 993-995. (doi:10.1124/mol.110.069427)
33. Fowler, C. J. 2012 Anandamide uptake explained? Trends Pharmacol. Sci. 33, 181-185. (doi:10.1016/j.tips.2012.01.001)
34. Fu, J. et al. 2011 A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat. Neurosci. 15, 64-69. (doi:10.1038/nn.2986)
35. Ligresti, A., Petrosino, S. & Di Marzo, V. 2009 From endocannabinoid profiling to 'endocannabinoid therapeutics'. Curr. Opin. Chem. Biol. 13, 321-331. (doi:10.1016/j.cbpa.2009.04.615)
36. Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sørgård, M., Di Marzo, V., Julius, D. & Högestätt, E. D. 1999 Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457. (doi:10.1038/22761)
37. De Petrocellis, L. & Di Marzo, V. 2010 Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J. Neuroimmune Pharmacol. 5, 103-121. (doi:10.1007/s11481-009-9177-z)
38. Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D. & Julius, D. 1997 The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816-824. (doi:10.1038/39807)
39. Starowicz, K., Nigam, S. & Di Marzo, V. 2007 Biochemistry and pharmacology of endovanilloids. Pharmacol. Ther. 114, 13-33. (doi:10.1016/j.pharmthera.2007.01.005)
40. Kim, J. & Alger, B. E. 2010 Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. Nat. Neurosci. 13, 592-600. (doi:10.1038/nn.2517)
41. Grueter, B. A., Brasnjo, G. & Malenka, R. C. 2010 Postsynaptic TRPV1 triggers cell type-specific long-term depression in the nucleus accumbens. Nat. Neurosci. 13, 1519-1525. (doi:10.1038/nn.2685)
42. Chávez, A. E., Chiu, C. Q. & Castillo, P. E. 2010 TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat. Neurosci. 13, 1511-1518. (doi:10.1038/nn.2684)
43. Maccarrone, M. et al. 2008 Anandamide inhibits metabolismand physiological actions of 2-arachidonoylglycerol in the striatum. Nat. Neurosci. 11, 152-159. (doi:10.1038/nn2042)
44. Alger, B. E. 2012 Endocannabinoids at the synapse a decade after the dies mirabilis (29 March 2001): what we still do not know. J. Physiol. 590, 2203-2212. (doi:10.1113/jphysiol.2011.220855)
45. Marinelli, S., Pacioni, S., Bisogno, T., Di Marzo, V., Prince, D. A., Huguenard, J. R. & Bacci, A. 2008 The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons. J. Neurosci. 28, 13532-13541. (doi:10.1523/JNEUROSCI.0847-08.2008)
46. Navarrete, M. & Araque, A. 2010 Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 68, 113-126. (doi:10.1016/j.neuron.2010.08.043)
47. Coiret, G., Ster, J., Grewe, B., Wendling, F., Helmchen, F., Gerber, U. & Benquet, P. 2012 Neuron to astrocyte communication via cannabinoid receptors is necessary for sustained epileptiform activity in rat hippocampus. PLoS ONE 7, e37320. (doi:10.1371/journal.pone.0037320)
48. Han, J. et al. 2012 Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 148, 1039-1050. (doi:10.1016/j.cell.2012.01.037)
49. Min, R. & Nevian, T. 2012 Astrocyte signaling controls spike timing-dependent depression at neocortical synapses. Nat. Neurosci. 15, 746-753. (doi:10.1038/nn.3075)
50. Fernández-Ruiz, J., Pazos, M. R., García-Arencibia, M., Sagredo, O. & Ramos, J. A. 2008 Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol. Cell. Endocrinol. 286(Suppl. 1), S91-S96. (doi:10.1016/j.mce.2008.01.001)
51. Stella, N. 2010 Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58, 1017-1030. (doi:10.1002/glia.20983)
52. Ahluwalia, J., Urban, L., Capogna, M., Bevan, S. & Nagy, I. 2000 Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 100, 685-688. (doi:10.1016/S0306-4522(00)00389-4)
53. Ahluwalia, J., Urban, L., Bevan, S., Capogna, M. & Nagy, I. 2002 Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive primary sensory neurones. Neuroscience 110, 747-753. (doi:10.1016/S0306-4522(01)00601-7)
54. Binzen, U., Greffrath, W., Hennessy, S., Bausen, M., Saaler-Reinhardt, S. & Treede, R. D. 2006 Coexpression of the voltage-gated potassium channel Kv1.4 with transient receptor potential channels (TRPV1 and TRPV2) and the cannabinoid receptor CB1 in rat dorsal root ganglion neurons. Neuroscience 142, 527-539. (doi:10.1016/j.neuroscience.2006.06.020)
55. Amaya, F., Shimosato, G., Kawasaki, Y., Hashimoto, S., Tanaka, Y., Ji, R. R. & Tanaka, M. 2006 Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 124, 175-183. (doi.org/10.1016/j.pain.2006.04.001)
56. Ralevic, V. & Kendall, D. A. 2009 Cannabinoid modulation of perivascular sympathetic and sensory neurotransmission. Curr. Vasc. Pharmacol. 7, 15-25. (doi:10.2174/157016109787354114)
57. Weller, K., Reeh, P. W. & Sauer, S. K. 2011 TRPV1, TRPA1, and CB1 in the isolated vagus nerve-axonal chemosensitivity and control of neuropeptide release. Neuropeptides 45, 391-400. (doi:10.1016/j.npep.2011.07.011)
58. Nucci, C. et al. 2007 Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats. Invest. Ophthalmol. Vis. Sci. 48, 2997-3004. (doi:10.1167/iovs.06-1355)
59. Cristino, L., de Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V. & Di Marzo, V. 2006 Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139, 1405-1415. (doi:10.1016/j.neuroscience.2006.02.074)
60. Maione, S., De Petrocellis, L., de Novellis, V., Moriello, A. S., Petrosino, S., Palazzo, E., Rossi, F. S., Woodward, D. F. & Di Marzo, V. 2007 Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br. J. Pharmacol. 150, 766-781. (doi:10.1038/sj.bjp.0707145)
61. Micale, V., Cristino, L., Tamburella, A., Petrosino, S., Leggio, G. M., Drago, F. & Di Marzo, V. 2009 Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34, 593-606. (doi:10.1038/npp.2008.98)
62. Golech, S. A., McCarron, R. M., Chen, Y., Bembry, J., Lenz, F., Mechoulam, R., Shohami, E. & Spatz, M. 2004 Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol. Brain Res. 132, 87-92. (doi.org/10.1016/j.molbrainres.2004.08.025)
63. Domenicali, M. et al. 2005 Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut 54, 522-527. (doi:10.1136/gut.2004.051599)
64. Moezi, L., Gaskari, S. A., Liu, H., Baik, S. K., Dehpour, A. R. & Lee, S. S. 2006 Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br. J. Pharmacol. 149, 898-908. (doi:10.1038/sj.bjp.0706928)
65. Lu, T., Newton, C., Perkins, I., Friedman, H. & Klein, T. W. 2006 Role of cannabinoid receptors in delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila. Eur. J. Pharmacol. 532, 170-177. (doi:10.1016/j.ejphar.2005.12.040)
66. Cavuoto, P., McAinch, A. J., Hatzinikolas, G., Janovská, A., Game, P. & Wittert, G. A. 2007 The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem. Biophys. Res. Commun. 364, 105-110. (doi:10.1016/j.bbrc.2007.09.099)
67. Brighton, P. J., McDonald, J., Taylor, A. H., Challiss, R. A., Lambert, D. G., Konje, J. C. & Willets, J. M. 2009 Characterization of anandamide-stimulated cannabinoid receptor signaling in human ULTR myometrial smooth muscle cells. Mol. Endocrinol. 23, 1415-1427. (doi:10.1210/me.2009-0097)
68. Rossi, F. et al. 2009 The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone 44, 476-484. (doi:10.1016/j.bone.2008.10.056)
69. Jenkin, K. A., McAinch, A. J., Grinfeld, E. & Hryciw, D. H. 2010 Role for cannabinoid receptors in human proximal tubular hypertrophy. Cell. Physiol. Biochem. 26, 879-886. (doi:10.1159/000323997)
70. Petrosino, S. et al. 2010 Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy 65, 698-711. (doi:10.1111/j.1398-9995.2009.02254.x)
71. Tóth, B. I. et al. 2011 Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. J. Invest. Dermatol. 131, 1095-1104. (doi:10.1038/jid.2010.421)
72. Pucci, M. et al. 2012 Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor. J. Biol. Chem. 287, 15466-15478. (doi:10.1074/jbc.M111.314880)
73. Miyashita, K., Oyama, T., Sakuta, T., Tokuda, M. & Torii, M. 2012 Anandamide induces matrix metalloproteinase-2 production through cannabinoid-1 receptor and transient receptor potential vanilloid-1 in human dental pulp cells in culture. J. Endod. 38, 786-790. (doi:10.1016/j.joen.2012.02.025)
74. Francavilla, F. et al. 2009 Characterization of the endocannabinoid system in human spermatozoa and involvement of transient receptor potential vanilloid 1 receptor in their fertilizing ability. Endocrinology 150, 4692-700. (doi:10.1210/en.2009-0057)
75. Schuelert, N., Zhang, C., Mogg, A. J., Broad, L. M., Hepburn, D. L., Nisenbaum, E. S., Johnson, M. P. & McDougall, J. J. 2010 Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain. Osteoarthr. Cartilage 18, 1536-1543. (doi:10.1016/j.joca.2010.09.005)
76. Hermann, H., De Petrocellis, L., Bisogno, T., Schiano Moriello, A., Lutz, B. & Di Marzo, V. 2003 Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell. Mol. Life Sci. 60, 607-616. (doi:10.1007/s000180300052)
77. De Petrocellis, L., Marini, P., Matias, I., Moriello, A. S., Starowicz, K., Cristino, L., Nigam, S. & Di Marzo, V. 2007 Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells. Exp. Cell Res. 313, 2993-3004. (doi:10.1016/j.yexcr.2007.05.012)
78. Di Marzo, V. 2010 Anandamide serves two masters in the brain. Nat. Neurosci. 13, 1446-1448. (doi:10.1038/nn1210-1446)
79. Szabo, B., Urbanski, M. J., Bisogno, T., Di Marzo, V., Mendiguren, A., Baer, W. U. & Freiman, I. 2006 Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J. Physiol. 577, 263-280. (doi:10.1113/jphysiol.2006.119362)
80. Cavanaugh, D. J. et al. 2011 Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. J. Neurosci. 31, 5067-5077. (doi:10.1523/JNEUROSCI.6451-10.2011)
81. Kauer, J. A. & Gibson, H. E. 2009 Hot flash: TRPV channels in the brain. Trends Neurosci. 32, 215-224. (doi:10.1016/j.tins.2008.12.006)
82. Matta, J. A. & Ahern, G. P. 2011 TRPV1 and synaptic transmission. Curr. Pharm. Biotechnol. 12, 95-101. (doi:10.2174/138920111793937925)
83. Musella, A., De Chiara, V., Rossi, S., Cavasinni, F., Castelli, M., Cantarella, C., Mataluni, G., Bernardi, G. & Centonze, D. 2010 Transient receptor potential vanilloid 1 channels control acetylcholine/2-arachidonoylglicerol coupling in the striatum. Neuroscience 167, 864-871. (doi:10.1016/j.neuro science.2010.02.058)
84. Puente, N., Cui, Y., Lassalle, O., Lafourcade, M., Georges, F., Venance, L., Grandes, P. & Manzoni, O. J. 2011 Polymodal activation of the endocannabinoid system in the extended amygdala. Nat. Neurosci. 14, 1542-1547. (doi:10.1038/nn.2974)
85. Musella, A., De Chiara, V., Rossi, S., Prosperetti, C., Bernardi, G., Maccarrone, M. & Centonze, D. 2009 TRPV1 channels facilitate glutamate transmission in the striatum. Mol. Cell. Neurosci. 40, 89-97. (doi:10.1016/j.mcn.2008.09.001)
86. Gibson, H. E., Edwards, J. G., Page, R. S., Van Hook, M. J. & Kauer, J. A. 2008 TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 57, 746-759. (doi:10.1016/j.neuron.2007.12.027)
87. Bennion, D. et al. 2011 Transient receptor potential vanilloid 1 agonists modulate hippocampal CA1 LTP via the GABAergic system. Neuropharmacology 61, 730-738. (doi:10.1016/j.neuropharm.2011.05.018)
88. Jensen, T. & Edwards, J. G. 2012 Calcineurin is required for TRPV1-induced long-term depression of hippocampal interneurons. Neurosci. Lett. 510, 82-87. (doi:10.1016/j.neulet.2012.01.006)
89. Cristino, L., Starowicz, K., De Petrocellis, L., Morishita, J., Ueda, N., Guglielmotti, V. & Di Marzo, V. 2008 Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience 151, 955-968. (doi:10.1016/j.neuroscience.2007.11.047)
90. Maione, S., Cristino, L., Migliozzi, A. L., Georgiou, A. L., Starowicz, K., Salt, T. E. & Di Marzo, V. 2009 TRPV1 channels control synaptic plasticity in the developing superior colliculus. J. Physiol. 587, 2521-2535. (doi:10.1113/jphysiol.2009.171900)
91. Häring, M., Guggenhuber, S. & Lutz, B. 2012 Neuronal populations mediating the effects of endocannabinoids on stress and emotionality. Neuroscience 204, 145-158. (doi:10.1016/j.neuroscience.2011.12.035)
92. Starowicz, K., Cristino, L. & Di Marzo, V. 2008 TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr. Pharm. Des. 14, 42-54. (doi:10.2174/138161208783330790)
93. Chahl, L. A. 2011 TRP channels and psychiatric disorders. Adv. Exp. Med. Biol. 704, 987-1009. (doi:10.1007/978-94-007-0265-3_51)
94. Talwar, R. & Potluri, V. K. 2011 Cannabinoid 1 (CB1) receptor-pharmacology, role in pain and recent developments in emerging CB1 agonists. CNS Neurol. Disord. Drug Targets 10, 536-544. (doi:10.2174/187152711796235005)
95. Murineddu, G., Asproni, B. & Pinna, G. A. A. 2012 Survey of recent patents on CB2 agonists in the management of pain. Recent Pat. CNS Drug Discov. 7, 4-24. (doi:10.2174/157488912798842214)
96. Jara-Oseguera, A., Simon, S. A. & Rosenbaum, T. 2008 TRPV1: on the road to pain relief. Curr. Mol. Pharmacol. 1, 255-269. (doi:10.2174/1874467210801030255)
97. Maione, S. et al. 2006 Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J. Pharmacol. Exp. Ther. 316, 969-982. (doi:10.1124/jpet.105.093286)
98. Pernía-Andrade, A. J. et al. 2009 Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 325, 760-764. (doi:10.1126/science.1171870)
99. Palazzo, E., Luongo, L., de Novellis, V., Berrino, L., Rossi, F. & Maione, S. 2010 Moving towards supraspinal TRPV1 receptors for chronic pain relief. Mol. Pain 6, 66. (doi:10.1186/1744-8069-6-66)
100. Kissin, I. & Szallasi, A. 2011 Therapeutic targeting of TRPV1 by resiniferatoxin, from preclinical studies to clinical trials. Curr. Top. Med. Chem. 11, 2159-2170. (doi:10.2174/156802611796904924)
101. Engel, M. A., Izydorczyk, I., Mueller-Tribbensee, S. M., Becker, C., Neurath, M. F. & Reeh, P. W. 2011 Inhibitory CB1 and activating/desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin. Neuropeptides 45, 229-237. (doi:10.1016/j.npep.2011.03.005).
102. Starowicz, K., Makuch, W., Osikowicz, M., Piscitelli, F., Petrosino, S., Di Marzo, V. & Przewlocka, B. 2012 Spinal anandamide produces analgesia in neuropathic rats:possible CB(1)- and TRPV1-mediated mechanisms. Neuropharmacology 62, 1746-1755. (doi:10.1016/j.neuropharm.2011.11.021)
103. Starowicz, K., Maione, S., Cristino, L., Palazzo, E., Marabese, I., Rossi, F., de Novellis, V. & Di Marzo, V. 2007 Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J. Neurosci. 27, 13739-13749. (doi:10.1523/JNEUROSCI.3258-07.2007)
104. Kawahara, H., Drew, G. M., Christie, M. J. & Vaughan, C. W. 2011 Inhibition of fatty acid amide hydrolase unmasks CB1 receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey. Br. J. Pharmacol. 163, 1214-1222. (doi:10.1111/j.1476-5381.2010.01157.x)
105. Liao, H. T., Lee, H. J., Ho, Y. C. & Chiou, L. C. 2011 Capsaicin in the periaqueductal gray induces analgesia via metabotropic glutamate receptormediated endocannabinoid retrograde disinhibition. Br. J. Pharmacol. 163, 330-345. (doi:10.1111/j.1476-5381.2011.01214.x)
106. Giordano, C. et al. In press. TRPV1-dependent andindependent alterations in the limbic cortex of neuropathic mice: impact on glial caspases and pain perception. Cereb. Cortex. (doi:10.1093/cercor/bhr328)
107. Knerlich-Lukoschus, F., Noack, M., von der Ropp-Brenner, B., Lucius, R., Mehdorn, H. M. & Held-Feindt, J. 2011 Spinal cord injuries induce changes in CB1 cannabinoid receptor and C-C chemokine expression in brain areas underlying circuitry of chronic pain conditions. J. Neurotrauma 28, 619-634. (doi:10.1089/neu.2010.1652)
108. De Petrocellis, L. & Di Marzo, V. 2005 Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. Life Sci. 77, 1651-1666. (doi:10.1016/j.lfs.2005.05.021)
109. Fioravanti, B. et al. 2008 Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. J. Neurosci. 28, 11593-11602. (doi:10.1523/JNEUROSCI.3322-08.2008)
110. Yuan, S. & Burrell, B. D. 2010 Endocannabinoiddependent LTD in a nociceptive synapse requires activation of a presynaptic TRPV-like receptor. J. Neurophysiol. 104, 2766-2777. (doi:10.1152/jn.00491.2010)
111. Hong, S., Fan, J., Kemmerer, E. S., Evans, S., Li, Y. & Wiley, J. W. 2009 Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat. Gut 58, 202-210. (doi:10.1136/gut.2008.157594)
112. Bab, I. & Zimmer, A. 2008 Cannabinoid receptors and the regulation of bone mass. Br. J. Pharmacol. 153, 182-188. (doi:10.1038/sj.bjp.0707593)
113. Idris, A. I. & Ralston, S. H. 2010 Cannabinoids and bone: friend or foe? Calcif. Tissue Int. 87, 285-297. (doi:10.1007/s00223-010-9378-8)
114. Rossi, F. et al. 2011 The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy. Bone 48, 997-1007. (doi:10.1016/j.bone.2011.01.001)
115. Di Marzo, V. & De Petrocellis, L. 2010 Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr. Med. Chem. 17, 1430-1449. (doi:10.2174/092986710790980078)
116. Tsumura, M., Sobhan, U., Muramatsu, T., Sato, M., Ichikawa, H., Sahara, Y., Tazaki, M. & Shibukawa, Y. 2012 TRPV1-mediated calcium signal couples with cannabinoid receptors and sodium-calcium exchangers in rat odontoblasts. Cell Calcium 52, 124-136. (doi:10.1016/j.ceca.2012.05.002).
117. Oz, M. 2006 Receptor-independent effects of endocannabinoids on ion channels. Curr. Pharm. Des. 12, 227-239. (doi:10.2174/138161206775193073)
118. Chemin, J., Monteil, A., Perez-Reyes, E., Nargeot, J. & Lory, P. 2001 Direct inhibition of T-type calciumchannels by the endogenous cannabinoid anandamide. EMBO J. 20, 7033-7040. (doi:10.1093/emboj/20.24.7033)
119. Chemin, J., Nargeot, J. & Lory, P. 2007 Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels. J. Biol. Chem. 282, 2314-2323. (doi:10.1074/jbc.M610033200)
120. Lambert, R. C., Bessaih, T. & Leresche, N. 2006 Modulation of neuronal T-type calcium channels. CNS Neurol. Disord. Drug Targets 5, 611-627. (doi:10.2174/187152706779025544)
121. Maingret, F., Patel, A. J., Lazdunski, M. & Honoréé, E. 2001 The endocannabinoid anandamide is a direct and selective blocker of the background K{thorn} channel TASK-1. EMBO J. 20, 47-54. (doi:10.1093/emboj/20.1.47)
122. Oz, M., Ravindran, A., Diaz-Ruiz, O., Zhang, L. & Morales, M. 2003 The endogenous cannabinoid anandamide inhibits alpha7 nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. J. Pharmacol. Exp. Ther. 306, 1003-1010. (doi:10.1124/jpet.103.049981)
123. Zaniewska, M., McCreary, A. C., Przegaliński, E. & Filip, M. 2006 Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. Eur. J. Pharmacol. 540, 96-106. (doi:10.1016/j.ejphar.2006.04.034)
124. Spivak, C. E., Lupica, C. R. & Oz, M. 2007 The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors. Mol. Pharmacol. 72, 1024-1032. (doi:10.1124/mol.107.036939)
125. Hejazi, N., Zhou, C., Oz, M., Sun, H., Ye, J. H. & Zhang, L. 2006 Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol. Pharmacol. 69, 991-997. (doi:10.1124/mol.105.019174)
126. Yang, Z., Aubrey, K. R., Alroy, I., Harvey, R. J., Vandenberg, R. J. & Lynch, J. W. 2008 Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. Biochem. Pharmacol. 76, 1014-1023. (doi:10.1016/j.bcp.2008.07.037)
127. Yévenes, G. E. & Zeilhofer, H. U. 2011 Molecular sites for the positive allosteric modulation of glycine receptors by endocannabinoids. PLoS ONE 6, e23886. (doi:10.1371/journal.pone.0023886)
128. Xiong, W., Wu, X., Lovinger, D. M. & Zhang, L. 2012 A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors. J. Neurosci. 32, 5200-5208. (doi:10.1523/JNEUROSCI.6347-11.2012)
129. Sigel, E., Baur, R., Rácz, I., Marazzi, J., Smart, T. G., Zimmer, A. & Gertsch, J. 2011 The major central endocannabinoid directly acts at GABA(A) receptors. Proc. Natl Acad. Sci. USA 108, 18150-18155. (doi:10.1073/pnas.1113444108)
130. Spivak, C. E., Kim, W., Liu, Q.-R., Lupica, C. R. & Doyle, M. E. 2012 Blockade of b-cell K(ATP) channels by the endocannabinoid, 2-arachidonoylglycerol. Biochem. Biophys. Res. Comm. 423, 13-16. (doi:10.1016/j.bbrc.2012.05.042)
131. Matias, I. et al. 2006 Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91, 3171-3180. (doi:10.1210/jc.2005-2679)
132. Li, C., Bowe, J. E., Jones, P. M. & Persaud, S. J. 2010 Expression and function of cannabinoid receptors in mouse islets. Islets 2, 293-302. (doi:10.4161/isl.2.5.12729)
133. Du, H., Chen, X., Zhang, J. & Chen, C. 2011 Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-g. Br. J. Pharmacol. 163, 1533-1549. (doi:10.1111/j.1476-5381.2011.01444.x)
134. Rockwell, C. E., Snider, N. T., Thompson, J. T., Vanden Heuvel, J. P. & Kaminski, N. E. 2006 Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 70, 101-111. (doi:10.1124/mol.105.019117)
135. Raman, P., Kaplan, B. L., Thompson, J. T., Vanden Heuvel, J. P. & Kaminski, N. E. 2011 15-Deoxydelta12,14-prostaglandin J2-glycerol ester, a putative metabolite of 2-arachidonyl glycerol, activates peroxisome proliferator activated receptor gamma. Mol. Pharmacol. 80, 201-209. (doi:10.1124/mol.110.070441)
136. Bouaboula, M., Hilairet, S., Marchand, J., Fajas, L., Le Fur, G. & Casellas, P. 2005 Anandamide induced PPAR-g transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol. 517, 174-181. (doi:10.1016/j.ejphar.2005.05.032)
137. Karaliota, S., Siafaka-Kapadai, A., Gontinou, C., Psarra, K. & Mavri-Vavayanni, M. 2009 Anandamide increases the differentiation of rat adipocytes and causes PPAR-g and CB1 receptor upregulation. Obesity (Silver Spring) 17, 1830-1838. (doi:10.1038/oby.2009.177)
138. Maccarrone, M., Barboni, B., Paradisi, A., Bernabò, N., Gasperi, V., Pistilli, M. G., Fezza, F., Lucidi, P. & Mattioli, M. 2005 Characterization of the endocannabinoid system in boar spermatozoa and implications for sperm capacitation and acrosome reaction. J. Cell Sci. 118, 4393-4404. (doi:10.1242/jcs.02536)
139. Gervasi, M. G., Osycka-Salut, C., Caballero, J., Vazquez-Levin, M., Pereyra, E., Billi, S., Franchi, A. & Perez-Martinez, S. 2011 Anandamide capacitates bull spermatozoa through CB1 and TRPV1 activation. PLoS ONE 6, e16993. (doi:10.1371/journal.pone.0016993)
140. Czifra, G., Varga, A., Nyeste, K., Marincsák, R., Tóth, B. I., Kovács, I., Kovács, L. & Bíró, T. 2009 Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J. Cancer Res. Clin. Oncol. 135, 507-514. (doi:10.1007/s00432-008-0482-3)
141. Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M. & Di Marzo, V. 2000 Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141, 118-126. (doi:10.1210/en.141.1.118)
142. Ramer, R. & Hinz, B. 2008 Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl Cancer Inst. 100, 59-69. (doi:10.1093/jnci/djm268)
143. Ross, H. R., Gilmore, A. J. & Connor, M. 2009 Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Br. J. Pharmacol. 156, 740-750. (doi:10.1111/j.1476-5381.2008.00072.x)
144. O'Sullivan, S. E. & Kendall, D. A. 2010 Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 215, 611-616. (doi:10.1016/j.imbio.2009.09.007)
145. Dodd, G. T., Mancini, G., Lutz, B. & Luckman, S. M. 2010 The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. J. Neurosci. 30, 7369-7376. (doi:10.1523/JNEUROSCI.5455-09.2010)
146. Heimann, A. S. et al. 2007 Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc. Natl Acad. Sci. USA 104, 20588-20593. (doi:10.1073/pnas.0706980105)
147. Gomes, I. et al. 2009 Novel endogenous peptide agonists of cannabinoid receptors. FASEB J. 23, 3020-3029. (doi:10.1096/fj.09-132142)